Active Clinical Trials
We are currently highlighting three pivotal clinical trials enrolling patients across leading U.S. sites: RESORB, VENOS-3, and FREEFLOW.
RESORB (Randomized Controlled Study Evaluating GAE vs Intra-Articular Corticosteroid Knee Injection)
- Pivotal clinical trial enrolling ~126 patients across 10+ leading U.S. clinical sites.
- Compares genicular artery embolization (GAE) with Nexsphere-F™ to intra-articular corticosteroid injections for painful knee osteoarthritis, assessing safety and efficacy.
- Nexsphere-F™: innovative resorbable microsphere technology that temporarily occludes abnormal blood flow in pain-inducing vessels.
- Microspheres dissolve within 2–6 hours, inducing targeted necrosis of nerve endings associated with osteoarthritis pain and delivering rapid, sustained pain relief.
- Usage: Widely used outside the United States for osteoarthritis and musculoskeletal pain.
- In the U.S., Nexsphere-F™ is available only through the RESORB clinical trial.
VENOS-3 (Velocity™ Percutaneous AVF System)
- Pivotal study for the Velocity™ Percutaneous AVF System (Venova Medical).
- Enrolling 126 patients across 10+ leading U.S. clinical sites.
- Purpose: Create an arteriovenous fistula (AVF) for hemodialysis access.
- Approach: Minimally-invasive alternative to major arm surgery to create a fistula or graft.
- Availability: Velocity™ is available only to patients enrolling in the VENOS-3 clinical trial.
FREEFLOW (VERSONO Medical FastWire System)
- Pivotal IDE study evaluating the FastWire System (VERSONO Medical).
- Enrolling up to 65 patients across 10+ leading U.S. clinical sites.
- Technology: Novel proprietary ultrasonic method to cross severe, complex arterial blockages above and below the knee.
- Goal: Assist in restoring blood flow in severe Chronic/Complex Total Occlusions (CTOs) in vulnerable patients to help prevent amputation.